Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Primary Hypereosinophilic Syndromes
NCT00787384Phase 2Completed
- Sponsor
- Northern Italy Leukemia Group
- Start
- Oct 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), sponsored by Northern Italy Leukemia Group. Started Oct 2004; status: completed.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)chronic eosinophilic leukemia (CEL)
Beyond the preview
Go deeper on NCT00787384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787384.